Stay updated on SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial

Sign up to get notified when there's something new on the SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    Version dated 2025-12-08 adds a 'Results Submitted' entry and updates the Study Status; the prior 2025-11-10 entry of 'No Results Posted' was removed.
    Difference
    0.2%
    Check dated 2025-12-08T17:50:08.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    Revision: v3.3.2 was added and Revision: v3.3.1 was removed from the record history. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2025-12-01T11:43:10.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Revision: v3.3.1 was added and Revision: v3.2.0 was removed from the page header/footer to reflect the latest site revision.
    Difference
    0.0%
    Check dated 2025-11-24T11:38:12.000Z thumbnail image
  4. Check
    29 days ago
    Change Detected
    Difference
    0.4%
    Check dated 2025-11-17T06:16:40.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    The history page shows the same version list with only minor visual/layout updates; no new study data or status updates are visible. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2025-11-03T00:48:19.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    New date entries and study status have been added, replacing an older dated item.
    Difference
    0.7%
    Check dated 2025-10-12T12:04:23.000Z thumbnail image

Stay in the know with updates to SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial page.